Plain-English translation of NCT07079605 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers want to understand how severe infections (sepsis) affect the heart in patients who don't have existing heart disease. The study will compare two groups of patients: those whose hearts show signs of damage during infection and those whose hearts appear unaffected. By following both groups for one year, researchers hope to learn which heart changes during infection predict worse outcomes and survival.
Severe infections often harm the heart and increase the risk of death, but doctors don't yet fully understand how this happens or how to predict which patients will have the worst outcomes—especially in countries with limited medical resources. This study will help fill that gap.
You likely qualify if…
You likely don't qualify if…
You will be assessed when you're admitted with severe infection using heart tests (blood tests, ECG, and ultrasound) to see if your heart is affected. Then you'll be placed in one of two groups based on whether your heart shows signs of damage. Over the next year, researchers will track your health through regular follow-up visits to see how your heart recovers and how well you do overall.
AI-generated summary from trial data · Aug 12, 2026 · Not medical advice
Ethiopia
Jimma University
Collaborators
Ethiopian Society of Cardiac Professionals
Enrollment target
~226 participants
Started
May 2025
Primary completion
May 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in July 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Kedir Negesso Tukeni, MD, Internist, Cardiologist
Ludwig Maximillians University of Munich, Germany
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.